CIK 0001650664 · Non-accelerated filer<br>Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464097528
- Phone
- 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,092
- in 3 filings, $19K under 10b5-1 plans
Net −$19,092. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −5,394 | $2.02 | $11K | 263,693 |
| 2026-03-03 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −474 | $2.02 | $957 | 15,434 |
| 2026-03-03 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −749 | $2.02 | $2K | 68,028 |
| 2025-12-03 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −713 | $2.15 | $2K | 68,777 |
| 2025-12-03 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −5,603 | $2.15 | $12K | 269,087 |
| 2025-12-03 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −461 | $2.15 | $993 | 15,908 |
| 2025-09-03 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −710 | $2.60 | $2K | 69,490 |
| 2025-09-03 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −458 | $2.60 | $1K | 16,369 |
| 2025-09-03 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −5,592 | $2.60 | $15K | 274,690 |
| 2025-08-07 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −679 | $2.58 | $2K | 16,827 |
| 2025-07-31 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −5,121 | $2.49 | $13K | 64,398 |
| 2025-06-06 | Hopfield Jessica Director | Grant or award · Stock Option (right to buy) | +37,500 | 37,500 | ||
| 2025-06-06 | Scadden David Director | Grant or award · Stock Option (right to buy) | +37,500 | 37,500 | ||
| 2025-06-06 | Levy Elliott M. Director | Grant or award · Stock Option (right to buy) | +37,500 | 37,500 | ||
| 2025-06-06 | Connaughton Bernadette Director | Grant or award · Stock Option (right to buy) | +37,500 | 37,500 | ||
| 2025-06-06 | Hirsch Andrew Director | Grant or award · Stock Option (right to buy) | +37,500 | 37,500 | ||
| 2025-06-03 | Parison Amy SVP, Chief Financial Officer | Sale 10b5-1 | −446 | $1.72 | $769 | 17,506 |
| 2025-06-03 | Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −726 | $1.72 | $1K | 69,519 |
| 2025-06-03 | O'Neill Gilmore Neil CEO | Sale 10b5-1 | −15,192 | $1.72 | $26K | 280,282 |
| 2025-04-08 | Parison Amy SVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +34,672 | 34,672 |
Page 2 of 15 · 283 trades